ORKA earnings analysis
What we found in ORKA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Oruka reported Q2 diluted EPS of -$0.55 and $0.0 revenue, with losses worsening from both Q1 2026 and Q2 2025. The company materially improved its funding position through a $658.3 million April offering and $161.4 million of ATM net proceeds as of July 31, 2026, but this came with substantial dilution and does not change its lack of commercial revenue. Clinical development progressed across ORKA-001 and ORKA-002, including a new ORKA-002 Phase 2 hidradenitis suppurativa trial, while sole-source manufacturing, BIOSECURE Act exposure, regulatory uncertainty, and continued losses remain significant risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Losses Worsened With No Revenue
- Q2 diluted EPS was -$0.55 versus -$0.48 in Q1 2026 and -$0.46 in Q2 2025, indicating sequential and year-over-year deterioration in losses. Revenue was $0.0, consistent with the company’s statement that it has never generated revenue from product sales.
- Substantial Capital Raised
- The company completed an April 2026 offering of 9,660,000 common shares for net proceeds of $658.3 million. It also generated $161.4 million of net proceeds from its ATM program as of July 31, 2026, materially strengthening available funding.
- Clinical Programs Continue Advancing
- ORKA-001 Phase 1 in healthy volunteers is fully enrolled and ongoing for follow-up, while its Phase 2a and Phase 2b psoriasis trials remain ongoing. ORKA-002 Phase 1 is also fully enrolled and ongoing, and a Phase 2 psoriasis trial began in February 2026.
- ORKA-002 Expands Into HS
- The company initiated a Phase 2 trial of ORKA-002 in hidradenitis suppurativa, expanding development beyond psoriasis and supporting the company’s focus on its two most advanced programs, ORKA-001 and ORKA-002.
- Controls Remained Effective
- Management concluded that disclosure controls were effective at the reasonable-assurance level as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Financing and Dilution Risk
- The company states that it will need to raise substantial additional capital and expects significant expenses and increasing operating losses for the foreseeable future. The April 2026 financing issued 9,660,000 shares, while the ATM program had produced $161.4 million of net proceeds as of July 31, 2026, highlighting both funding capacity and dilution risk.
- Sole-Source and BIOSECURE Exposure
- The company relies on a sole-source relationship for ORKA-001 and ORKA-002 manufacturing and currently relies on foreign CROs and CMOs, including WuXi Biologics. The filing states that designation under the BIOSECURE Act could require a provider transition, causing supply disruptions or higher costs.
- Concentrated Clinical Risk
- Development is concentrated in two advanced programs, ORKA-001 and ORKA-002. ORKA-001 has ongoing Phase 2a and Phase 2b psoriasis trials, while ORKA-002 began Phase 2 psoriasis development in February 2026 and recently entered Phase 2 hidradenitis suppurativa development; delays, safety issues, or inconclusive data could materially impair the pipeline.
- Potential FDA Review Delays
- The filing adds or emphasizes uncertainty from potential FDA disruption, noting mass federal-government layoffs since January 2025 and the possibility that reductions in FDA staffing or funding could lengthen review periods and delay clinical development.
- No Commercial Revenue or Profit
- The company has never generated revenue from product sales and states it may never become profitable. Q2 diluted EPS was -$0.55, compared with -$0.46 in Q2 2025, underscoring the ongoing operating-loss profile.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.55
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management states it expects to continue incurring significant expenses and increasing operating losses for the foreseeable future; development milestones remain subject to change.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Oruka Therapeutics reported substantial operating losses in Q1 2026, with a net loss of $31.8 million compared to a loss of $21 million in Q1 2025, marking a 52% increase. Cash and cash equivalents stood at $496…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ORKA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever